Veterinary Clinical Trials

Global Veterinary Clinical Trials Market to Reach US$7.6 Billion by 2030

The global market for Veterinary Clinical Trials estimated at US$5.2 Billion in the year 2024, is expected to reach US$7.6 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Companion Animal, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Livestock Animal segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Veterinary Clinical Trials market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Veterinary Clinical Trials Market – Key Trends & Drivers Summarized

Why Are Veterinary Clinical Trials Gaining Prominence in Modern Animal Health Research?

Veterinary clinical trials are becoming an essential part of animal health innovation, driven by the growing demand for safe, effective, and evidence-based treatments in both companion and livestock animals. As veterinary medicine continues to evolve in complexity and sophistication—mirroring advancements in human healthcare—there is an increasing need to validate new drugs, vaccines, biologics, devices, and therapies through rigorous, structured clinical testing. These trials are critical for assessing efficacy, safety, dosing protocols, and potential side effects before commercial launch. The rise in chronic diseases, zoonotic threats, antimicrobial resistance, and age-related conditions among pets and farm animals is intensifying the pressure to bring new veterinary products to market. At the same time, pet owners and livestock producers alike are seeking improved treatment outcomes, leading to greater interest in precision veterinary medicine, personalized nutrition, and targeted therapeutics. This changing landscape has made veterinary clinical trials more relevant than ever, with a rising number of veterinary research organizations (CROs), academic institutions, pharmaceutical companies, and regulatory agencies placing strong emphasis on preclinical and clinical research that complies with global safety and ethical standards.

How Is Technology Enhancing the Design and Execution of Veterinary Trials?

Technological innovation is revolutionizing how veterinary clinical trials are designed, monitored, and analyzed—making them faster, more data-driven, and compliant with evolving regulations. Electronic data capture (EDC) systems and cloud-based trial management platforms are enabling real-time data collection, remote monitoring, and secure sharing between research sites, veterinarians, and sponsors. Wearable devices and sensor-based collars are now being used to gather continuous physiological data on animals during trials, such as heart rate, activity levels, and body temperature, providing richer insights without causing stress or requiring repeated clinic visits. AI and machine learning algorithms are being applied to analyze large datasets, identify trends, and improve patient recruitment by matching animals to relevant trials based on breed, age, condition, and location. Mobile apps and telemedicine tools are also supporting virtual consultations and at-home data collection, particularly in long-term chronic disease trials. These digital tools are helping streamline trial logistics, reduce human error, and improve participant retention, while also enhancing transparency for pet owners and farm managers. Overall, these technologies are not only optimizing the operational side of veterinary trials but are also raising the standard of scientific evidence generated in veterinary medicine.

Why Are Pharma Companies, CROs, and Veterinary Clinics Expanding Their Clinical Trial Activity?

Pharmaceutical companies, contract research organizations (CROs), and veterinary clinics are significantly expanding their investment in clinical trial infrastructure to meet growing regulatory demands and accelerate innovation in the veterinary therapeutics space. Animal health companies are increasingly focusing on developing specialized products for conditions like osteoarthritis, cancer, diabetes, dermatological disorders, and infectious diseases—areas that require rigorous clinical validation before entering the market. As the veterinary drug pipeline expands, CROs are partnering with veterinary practices and academic institutions to conduct multicenter trials that ensure data reliability and demographic diversity. Veterinary clinics—especially those affiliated with universities or large networks—are establishing research arms to enroll patients in trials, giving pet owners access to cutting-edge treatments while contributing to scientific advancement. Additionally, livestock producers and agribusiness stakeholders are working with animal health companies to test products that improve herd productivity, disease resistance, and food safety. Regulatory bodies such as the FDA (Center for Veterinary Medicine), EMA (CVMP), and other national authorities have strengthened guidance around Good Clinical Practice (GCP) for veterinary studies, which is increasing compliance costs but also professionalizing the entire ecosystem. This surge in collaborative, well-structured trial activity reflects a maturing market that is embracing data-backed innovation as the foundation of future animal health solutions.

What’s Driving the Global Growth of the Veterinary Clinical Trials Market?

The growth in the veterinary clinical trials market is driven by several interrelated factors tied to rising pet ownership, livestock health priorities, regulatory evolution, and technological advancement. One of the most significant drivers is the growing prevalence of chronic and lifestyle-related diseases in companion animals, which has increased demand for new treatment modalities and preventive solutions. Meanwhile, livestock health remains a high priority for ensuring global food security and sustainability, especially in the face of emerging diseases, climate change, and antibiotic resistance. The increasing willingness of pet owners to participate in clinical studies—fueled by better education, trust in veterinary science, and access to novel therapies—is improving recruitment and study success rates. At the same time, global harmonization of regulatory standards for veterinary products is encouraging pharmaceutical companies to invest in cross-border trials that facilitate faster approvals. The rise of veterinary-specific CROs and digital trial management tools is also improving trial scalability and efficiency, making research more accessible to clinics of all sizes. Additionally, the growth of pet insurance, specialty practices, and university-affiliated animal hospitals is creating more opportunities to conduct structured, large-scale research. These collective trends are turning veterinary clinical trials into a critical growth engine for the animal health industry, accelerating the delivery of innovative solutions for pets, livestock, and the veterinarians who care for them.

SCOPE OF STUDY:

The report analyzes the Veterinary Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Animal (Companion Animal, Livestock Animal, Other Animals); Indication (Oncology, Internal Medicine, Orthopedics, Cardiology, Neurology, Ophthalmology, Dermatology, Other Indication); Intervention (Medicines, Medical Devices, Others); Sponsor (Pharma & Biopharma Companies, Academics & Research Centers, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AGLAIA
• Animal Health Consultants
• Argenta
• Biotest Lab
• Cebiphar
• Charles River Laboratories
• Clinvet
• Cloudbyz
• ERBC
• IDEXX Laboratories
• Inotiv
• KLIFOVET GmbH
• knoell
• Labcorp Drug Development
• Löhlein & Wolf Vet Research
• Oncovet Clinical Research (OCR)
• Premier Research
• QTest Labs
• Scantox
• STATKING Clinical Services

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.